You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20 positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)

Not yet recruiting
  • Resolved Hepatitis B
  • CD20 Positive B-cell Lymphoma
  • (no location specified)
Jul 10, 2022

Hematological Tumors Trial in Beijing (TQB2825 injection)

Recruiting
  • Hematological Tumors
  • TQB2825 injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

CD20-positive B-cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant anti-CD20 mAb-MMAE coupling agent for injection

Recruiting
  • CD20-positive B-cell Non-Hodgkin Lymphoma
  • Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences, Cancer Hospital
May 24, 2022

CD20 Positive Non Hodgkin Lymphoma Trial in United States (CPO107)

Recruiting
  • CD20 Positive Non Hodgkin Lymphoma
  • Los Angeles, California
  • +4 more
Aug 9, 2022

Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

Withdrawn
  • Leukemia
  • Stem Cell Transplantation
  • Munich, Bavaria, Germany
    3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022

B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • (no location specified)
Mar 6, 2023

B-cell Non-Hodgkin's Lymphoma Trial in Cincinnati (IMM0306)

Recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Cincinnati, Ohio
    The Christ Hospital
Apr 1, 2022

B-cell Non Hodgkin's Lymphoma Trial (HLX01, Rituximab)

Completed
  • B-cell Non Hodgkin's Lymphoma
  • (no location specified)
May 4, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

CD20 Positive B Cell Non-Hodgkin's Lymphoma Trial in Guangzhou, Tianjin (B001)

Completed
  • CD20 Positive B Cell Non-Hodgkin's Lymphoma
  • B001
  • Guangzhou, Guangdong, China
  • +1 more
Nov 11, 2021

Lymphoma Trial (BYON4228 + Rituximab)

Not yet recruiting
  • Lymphoma
  • BYON4228 + Rituximab
  • (no location specified)
Feb 20, 2023

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory Trial in Cologne,

Active, not recruiting
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • +3 more
  • MB-CART20.1
  • Cologne, Germany
  • +1 more
Sep 20, 2021

CD20-positive B Cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection)

Completed
  • CD20-positive B Cell Non-Hodgkin Lymphoma
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences (CAMS) & Peking Union Medica
Jun 15, 2021

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Aggressive Non-Hodgkin Lymphoma Trial in Belgium, France (drug, other, procedure)

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • Brugge, Belgium
  • +21 more
Jan 9, 2023

Lymphoma, Large B-Cell, Diffuse Trial in China (Rituximab IV, Rituximab SC, Cyclophosphamide)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Rituximab IV
  • +7 more
  • Beijing, China
  • +9 more
Apr 6, 2022

Non Hodgkin Lymphoma Trial (biological, drug, radiation)

Withdrawn
  • Non Hodgkin Lymphoma
  • avelumab
  • +13 more
  • (no location specified)
Mar 17, 2021

Follicular Lymphoma Trial in United States (DRL_RI (Proposed rituximab biosimilar), MabThera®)

Active, not recruiting
  • Follicular Lymphoma
  • DRL_RI (Proposed rituximab biosimilar)
  • MabThera®
  • Whittier, California
  • +3 more
May 27, 2022

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

Recruiting Trial in Linyi (H02+CHOP, Rituxan +CHOP)

Recruiting
  • Recruiting
  • Linyi, Shandong, China
    Shandong New Time Pharmaceutical Co., LTD
Sep 7, 2021